Welcome to our dedicated page for Corvex news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Corvex stock.
Movano Inc. (Nasdaq: MOVE), doing business as Movano Health, generates news at the intersection of wearable medical devices, health technology, and corporate transformation. Founded in 2018, the company develops devices such as the Evie and EvieMED rings, which are designed to bring medical-grade data into consumer and enterprise wearables. Its disclosures highlight capabilities that span physiological monitoring, women’s wellness, and proprietary RF-based sensing for cuffless blood pressure and noninvasive glucose monitoring.
News coverage of Movano frequently includes product and technology updates. The company has announced clinical study results for its wrist-worn cuffless blood pressure prototype, noting accuracy within standards recognized by the FDA for wearable, cuffless blood pressure devices and the ability to collect additional vital signs such as pulse rate, SpO2, respiration rate and ECG waveforms. It has also reported enhancements to the Evie Ring’s companion app, including new personalization and trend-tracking features, integration with Apple Health, expanded workout logging, and the introduction of EvieAI, a virtual wellness assistant built from medical journal data.
Movano’s news flow also reflects regulatory and listing developments. The company has issued multiple press releases regarding Nasdaq notifications related to bid price, periodic filing timeliness, and stockholders’ equity requirements, as well as its responses, such as engaging a new independent auditor, submitting compliance plans, and implementing a one-for-ten reverse stock split to support bid price compliance. Investors following MOVE news can track how these steps affect the company’s continued listing on the Nasdaq Capital Market.
A significant portion of recent headlines centers on strategic and transactional events. Movano’s board initiated a process to explore strategic alternatives, including a sale or merger, to maximize shareholder value. This process led to a definitive Agreement and Plan of Merger with Corvex, Inc., an AI cloud computing company specializing in GPU-accelerated infrastructure. Related announcements describe the planned all-stock combination, ownership structure expectations, concurrent financings, and the intention to rename Movano Inc. as Corvex, Inc. upon closing, with the combined company headquartered in Arlington, Virginia. Movano has also communicated that it may market for sale its current operating assets, including the EvieMED Ring and its mmWave RF technology, prior to completion of the merger.
By monitoring the MOVE news feed, readers can follow updates on Movano’s wearable health products, clinical and regulatory milestones, listing status, financing activities, and the progress of its proposed merger with Corvex. This stream of information helps investors and observers understand both the company’s health technology initiatives and its potential evolution into a public vehicle for AI infrastructure through the planned combination.
Movano Health (MOVE) reported Q3 2024 results, highlighting three key initiatives: the successful back-in-stock launch of Evie Ring direct-to-consumer business, pursuing FDA 510(k) clearance for EvieMED Ring, and advancing blood pressure and glucose monitoring studies. The company shipped 339 Evie Rings in Q3, reporting an operating loss of $7.4 million compared to $9.1 million in Q3 2023. Cash position stood at $11.3 million as of September 30, 2024. The company implemented a 1-for-15 reverse stock split and regained Nasdaq compliance. They also entered agreement phase with a healthcare company for an EvieMED Ring pilot program in Q1 2025.
Movano Health (Nasdaq: MOVE) has completed testing of its new blood pressure wrist wearable during a hypoxia clinical trial at UC San Francisco. The enhanced device features 12 additional mmWave antennas and a custom IC, delivering improved data collection with a slimmer, more comfortable design. The wearable also monitors vital signs including pulse rate, blood oxygen saturation, respiration rate, and ECG waveforms.
This study follows two clinical trials from October 2023 and June 2024, where the company's non-invasive device collected pulse pressure waveforms data from over 50 participants. The device improvements were implemented based on learnings from these previous studies to achieve higher fidelity blood pressure signals.
Movano Health (Nasdaq: MOVE) has scheduled its third quarter 2024 financial results release for Thursday, November 14, 2024, after market close. The company will host a conference call and live audio webcast at 2:00 PM PT/5:00 PM ET on the same day. Investors can access the webcast through the company's investor relations website or join via phone using provided domestic and international dial-in numbers. A recorded version will be available on the company's website for two years.
Movano Health (NASDAQ: MOVE) has submitted a complete response package to the FDA for the final review phase of its 510(k) application for the EvieMED Ring. The company remains optimistic about receiving 510(k) clearance for this wearable device. The EvieMED Ring combines medical functionality through pulse oximetry with wellness tracking features, including sleep monitoring, activity tracking, and mood and energy logging capabilities. The company sees potential opportunities in remote patient monitoring and clinical trials markets.
Movano Health (MOVE) is investigating apparent stock manipulation following its recent reverse stock split. The company detected suspicious trading activity between October 25-29, 2024, involving numerous single-share transactions seemingly aimed at exploiting the fractional shares round-up convention. Movano identified this activity before any round-up shares were issued and maintains its expected post-split outstanding shares at approximately 6.6 million. The company is working with securities regulators and legal advisors to address this issue, noting that other small-cap stocks have faced similar manipulation attempts following their reverse splits.
Movano Health (Nasdaq: MOVE) has initiated an investigation into suspected stock manipulation following their recent reverse stock split. The company's CEO, John Mastrototaro, stated they are working with securities regulators, legal counsel, and other partners to protect shareholder interests. The company noted that several other small-cap stocks have experienced similar manipulation after implementing reverse stock splits. The reverse stock split was approved by shareholders at the annual meeting on July 9, 2024, with details available in the proxy statement filed on May 28, 2024.
Movano Health (Nasdaq: MOVE) has announced a brand partnership with lifestyle content creator Heidi D'Amelio, who will share her experiences with the Evie Ring to her 12 million Instagram and TikTok followers. The Evie Ring, priced at $269 with no subscription fees, is the first smart ring designed specifically for women, featuring an open design for finger size fluctuations and AI-powered health tracking. D'Amelio will provide product feedback to help improve the Evie app. The company recently restocked the product and plans to release an Android version in November 2024.
Movano Health (Nasdaq: MOVE) announced a 1-for-15 reverse stock split effective October 29, 2024. The split will reduce outstanding shares from approximately 99.5 million to 6.6 million, with the stock continuing to trade on Nasdaq under 'MOVE'. The reverse split aims to increase the bid price to meet Nasdaq's minimum requirements for continued listing. The measure was authorized by stockholders on July 9, 2024. Fractional shares will be rounded up to the next whole share, and proportionate adjustments will be made to equity plans. The company's transfer agent, Pacific Stock Transfer Company, will handle the exchange process.
Movano Health (Nasdaq: MOVE) announced plans to submit responses next week to FDA's clarifying questions regarding their 510(k) application for EvieMED. The company previously received positive feedback on EvieMED's wellness features and metrics this summer. The EvieMED Ring is designed as a wearable device combining medical functionality through pulse oximetry with wellness metrics tracking for sleep, activity, mood, and energy. The company aims to provide a consumer-friendly solution for remote patient monitoring and clinical trials to improve patient compliance and data collection.
Movano Health (Nasdaq: MOVE) provided an update on the FDA review of its EvieMED Ring. The company received additional clarifying questions from the FDA related to medical aspects of the device, as part of the final phase of its 510(k) application review process. Movano Health remains optimistic about EvieMED's potential for 510(k) clearance after securing a positive resolution to initial FDA questions about wellness features and metrics.
The EvieMED Ring is designed to provide medical device functionality through pulse oximetry, along with wellness metrics for sleep, activity, and mood tracking. Separately, Movano Health successfully resumed direct-to-consumer orders for the Evie Ring on September 17, 2024, with initial positive response to product and operational improvements.